Phospholipase A2: Quo vadis?

Journal of Rheumatology

Volumn 32, Issue 3, 2005, Pages 400-401

  Pruzanski, Waldemar ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; ARACHIDONIC ACID; FATTY ACID; GLYCEROPHOSPHOLIPID; LY 311727; LY 333013; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; STEROID; UNCLASSIFIED DRUG; VARESPLADIB; ENZYME INHIBITOR; PHOSPHOLIPASE A;

CATALYST; CLINICAL TRIAL; EDITORIAL; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HYDROLYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; SYNOVITIS; ANIMAL; DRUG ANTAGONISM; IMMUNOLOGY; INFLAMMATION; METABOLISM; NOTE;

ANIMALS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; ENZYME INHIBITORS; HUMANS; INFLAMMATION; PHOSPHOLIPASES A;

EID: 15044359853     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (35)

1. Vadas P, Hay JB. The release of phospholipase A2 from aggregated platelets and stimulated macrophages of sheep. Life Sci 1980;26:1721-9.
2. Seilhamer J, Pruzanski W, Vadas P, et al. Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid. J Biol Chem 1989;264:5335-8.
3. Vadas P, Pruzanski W. The role of extracellular phospholipase A2 in inflammation. Adv Inflamm Res 1983;7:51-62.
4. Vadas P, Browning J, Edelson J, et al. Extracellular phospholipase A2 expression and inflammation: the relationship with associated disease states. J Lipid Mediat 1993;8:1-30.
5. Pruzanski W, Vadas P, Browning J. Secretory non-pancreatic group II phospholipase A2: role in physiologic and inflammatory processes. J Lipid Mediat 1993;8:161-7.
6. Vadas P, Pruzanski W, Stefanski E, et al. Extracellular phospholipase A2 secretion is a common effector pathway of interleukin-1 and tumour necrosis factor action. Immunol Lett 1991;28:187-94.
7. Vadas P, Pruzanski W. Role of secretory phospholipase A2 in the pathobiology of disease. Lab Invest 1986;55:391-404.
8. Nakano T, Ohara O, Teraoka H, et al. Glucocorticoids suppress group II phospholipase A2 production by blocking mRNA synthesis and posttranscriptional expression. J Biol Chem 1990;265:12745-8.
9. Murakami M, Nakatani Y, Atsumi GI, Inoue K, Kudo I. Regulatory functions of phospholipase A2. Crit Rev Immunol 1997;17:225-83.
10. Balsinde J, Balboa MA, Insel PA, et al. Regulation and inhibition of phospholipase A2. Annu Rev Pharmacol Toxicol 1999;39:175-89.
11. Murakami M, Kudo I. Diversity and regulatory functions of mammalian secretory phospholipase A2s. Adv Immunol 2001;77:163-94.
12. Cupillard L, Koumanov K, Mattei MG. Cloning, chromosomal mapping and expression of a novel human secretory phospholipase A2. J Biol Chem 1997;272:15745-52.
13. Murakami M, Shimbara S, Kambe T, et al. The functions of five distinct mammalian phospholipase A2s in regulating arachidonic acid release. Type IIA and type V secretory phospholipase A2s are functionally redundant and act in concert with cytosolic phospholipase A2. J Biol Chem 1998;273:14411-23.
14. Sawada H, Murakami M, Enomoto A, et al. Regulation of type V phospholipase A2 expression and function by proinflammatory stimuli. Eur J Biochem 1999;263:826-33.
15. Valentin E, Singer AG, Ghomashchi F, Lazdunski M, Gelb MH, Lambeau G. Cloning and recombinant expression of human group IIF-secreted phospholipase A2. Biochem Biophys Res Commun 2000;279:223-8.
16. Six DA, Dennis EA. The expanding superfamily of phospholipase A2 enzymes: classification and characterization. Biochim Biophys Acta 2000;1488:1-19.
17. Cho W. Structure, function and regulation of group V phospholipase A2. Biochim Biophys Acta 2000;1488:48-58.
18. Murakami M, Kudo I. Diversity of phospholipase A2 enzymes: secretory phospholipase A2. Biol Pharm Bull 2004;27:1158-64.
19. Pruzanski W, Stefanski E, de Beer FC, et al. Lipoproteins are substrates for human secretory group IIA phospholipase A2: preferential hydrolysis of acute phase HDL. J Lipid Res 1998;39:2150-60.
20. 2, in the treatment of rheumatoid arthritis. J Rheumatol 2005;32:417-23.
21. Pruzanski W, Keystone EC, Sternby B, et al. Serum phospholipase A2 correlates with disease activity in rheumatoid arthritis. J Rheumatol 1988;15:1351-5.
22. Koo Seen Lin M, Farewell V, Vadas P, et al. Secretory phospholipase A2 as an index of disease activity in rheumatoid arthritis. Prospective double blind study of 212 patients. J Rheumatol 1996;23:1162-6.
23. Vadas P, Stefanski E, Pruzanski W. Characterization of extracellular phospholipase A2 in rheumatoid synovial fluid. Life Sci 1985;36:579-87.
24. Stefanski E, Pruzanski W, Sternby B, et al. Purification of a soluble phospholipase A2 from synovial fluid in rheumatoid arthritis. J Biochem 1986;100:1297-303.
25. Pruzanski W, Scott K, Smith G, et al. Enzymatic activity and immunoreactivity of extracellular phospholipase A2 in inflammatory synovial fluids. Inflammation 1992;16:437-43.
26. Vadas P, Pruzanski W, Kim J, et al. The proinflammatory effect of intra-articular injection of soluble human and venom phospholipase A2. Am J Pathol 1989;134:807-11.
27. Bomalaski JS, Lawton P. Browning JL. Human extracellular recombinant phospholipase A2 induces an inflammatory response in rabbit joints. J Immunol 1991;146:3904-10.
28. Cirino G, Cicala C, Sorrentino L, et al. Recombinant secreted non-pancreatic phospholipase A2 induces a synovitis-like inflammation in the rat air pouch. J Rheumatol 1994;21:824-9.
29. Vadas P, Pruzanski W, Sos A, et al. Synthesis and secretion of soluble phospholipase A2 from cultured osteoblasts [abstract]. Arthritis Rheum 1987;30 Suppl:S65.
30. Pruzanski W, Bogoch E, Katz A, et al. Induction of release of secretory nonpancreatic phospholipase A2 from human articular chondrocytes. J Rheumatol 1995;22:2114-9.
31. Bomalaski JS, Clark MA. Phospholipase A2 and arthritis. Arthritis Rheum 1993;36:190-8.
32. Pruzanski W, Vadas P, Stefanski E, et al. Phospholipase A2 actvity in sera and synovial fluids in rheumatoid arthritis and osteoarthritis: its possible role as a proinflammatory enzyme. J Rheumatol 1985;12:211-6.
33. Pinto F, Brenner T, Dan P, et al. Extracellular phospholipase A2 inhibitors suppress central nervous system inflammation. Glia 2003;44:275-82.
34. Thwin MM, Douni E, Aidinis V, et al. Effect of phospholipase A2 inhibitory peptide on inflammatory arthritis in a TNF transgenic mouse model: a time-course ultrastructural study. Arthritis Res Ther 2004;6:R2282-94.
35. Chen Y, Dennis EA. Expression and characterization of human group V phospholipase A2. Biochim Biophys Acta 1998;1394:57-64.